Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Enrolling by invitationPhase 1 A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Administration of LYN101 in Healthy Subjects and Multiple Administrations in Postmenopausal Women With Low Bone Mass
This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A) and multiple doses in postmenopausal women with low bone mass (part B).
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Administration of LYN101 in Healthy Subjects and Multiple Administrations in Postmenopausal Women with Low Bone Mass
100 Clinical Results associated with SHANGHAI TTM-BIO TECHNOLOGY CO., LTD.
0 Patents (Medical) associated with SHANGHAI TTM-BIO TECHNOLOGY CO., LTD.
100 Deals associated with SHANGHAI TTM-BIO TECHNOLOGY CO., LTD.
100 Translational Medicine associated with SHANGHAI TTM-BIO TECHNOLOGY CO., LTD.